The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase I trial of LY4152199, a BAFF-R-targeting bispecific, in previously treated B-cell malignancies
In this video, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, briefly introduces the upcoming first-in-human Phase I trial (NCT07101328) of LY4152199, a B-cell activation factor receptor (BAFF-R)-targeting bispecific antibody, in patients with previously treated B-cell malignancies. Dr Patel highlights that this trial is significant because it explores a novel target, BAFF-R, which may offer an alternative for patients who have been exposed to existing CD19- and CD20-targeting therapies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a really exciting trial we’re about to kick off. So I think as we recognize bispecific T-cell engagers have been really important developments in B-cell lymphomas. One of the challenges we’ve had to date is we have had limited targets. So we have CD19 and CD20 bispecifics. There are lots of other therapies that target those two antigens. So this trial is actually looking at a novel bispecific that targets a new B-cell-specific target called BAFF-R...
This is a really exciting trial we’re about to kick off. So I think as we recognize bispecific T-cell engagers have been really important developments in B-cell lymphomas. One of the challenges we’ve had to date is we have had limited targets. So we have CD19 and CD20 bispecifics. There are lots of other therapies that target those two antigens. So this trial is actually looking at a novel bispecific that targets a new B-cell-specific target called BAFF-R. So this is really exciting because as we see more and more patients exposed to CD19 and CD20 targeting therapies, we’re going to need other therapies. This trial is poised to help us understand whether BAFF-R can be a target with the use of a bispecific that targets BAFF-R.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
